Mylan ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies.
Indian Drugs & Pharmaceuticals Limited (I.D.P.L.) is a Central Public Sector Undertaking wholly owned by the Govt. of India engaged in manufacture of pharmaceuticals. A Unit of I.D.P.L. situated at Rishikesh requires to engage trained and experienced professionals in following fields on a fixed term contract basis initially for a period of on e year which can be extended further on performance basis.
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovativemedicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
Eisai Co., Ltd. based in Tokyo, Japan is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
HLL Biotech Limited (HBL) is a 100% subsidiary of HLL Lifecare Limited, a Mini Ratna Schedule B Central Public Sector Enterprise under the Ministry of Health & Family Welfare. HBL is setting up a vaccine complex at Chengalpett, Chennai for manufacturing of Bacterial and Viral Vaccines & developing a strong R&D base for vaccine technologies within the country.
Indian Drugs and Pharmaceuticals Limited (IDPL) is a Central Public Sector Undertaking wholly owned by the Government of India engaged in manufacture of pharmaceuticals with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur.
Multani Research Foundation was established with an objective to develop & deliver best Quality Drugs affordable by needed ones based on scientific rationale and knowledge of Ayurveda. To meet its expansion plan in the area of new range of FMCG and Herbal Drugs development required following personnel.
Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.